Intrexon, Ziopharm rise after Sleeping Beauty deal

Ziopharm Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp. (NYSE:XON) licensed chimeric antigen receptor (CAR) T cell technology from the University of Texas MD Anderson Cancer Center (Houston, Texas) that the companies said will allow them to bring as many as five cancer therapies into the clinic this year.

Ziopharm jumped $3.13 (55%) to $8.87 on Wednesday, giving it a market cap of $908.3 million. Intrexon jumped $8.93 (31%) to $37.30 and has a market cap of $3.7 billion. ...